IMV (formerly Immunovaccine) is developing a viral vaccine, using its proprietary DepoVax™ technology, for the treatment of Zika virus infection. DepoVax™ is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a specific and sustained immune response with single-dose effectiveness. Preclinical development is underway in Canada.
In May 2018, Immunovaccine changed its name to IMV  .
As at October 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection (Prevention) in Canada (Parenteral).
In April 2016, Immunovaccine and Leidos entered into a collaborative agreement to develop a vaccine against Zika virus infections. Under the terms of the agreement, Leidos will discover antigen candidates, utilising its Virtual Pharmaceutical Development Program, and Immunovaccine will formulate best of them in its DepoVax™ delivery system for preclinical testing  .
Key Development Milestones
In June 2016, Immunovaccine reported closing of a bought deal private placement, from which net proceeds of $US8 002 500 will be used for progressing the development of the company's cancer and infectious vaccine candidates and also for general corporate and working capital purposes  .
The vaccine delivery formulation, DepoVax™, is patent protected  .